Leprosy Treatment Market Anlysis with Inputs from Industry Experts 2018 to 2026 Leprosy Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Leprosy or Hansen's disease (HD) is a chronic infection caused by Mycobacterium lepromatosis or Mycobacterium leprae bacteria. Leprosy is principally a granulomatous disease. Symptoms of leprosy include reddish skin lesions, loss of sensation, and weakness of hands and muscles. Nerve damage is the primary cause for numbness of muscles. Leprosy is a communicable disease that can be propagated through contact with cough or phlegm of the affected person. Other risk factors of leprosy include malnutrition and weak immune system. Leprosy is especially prevalent in low-income countries. Leprosy Treatment Market Outlook According to the statistics received by the World Health Organization (WHO), from various regions (138 countries), the number of registered cases of leprosy was 176,176 in 2015, that is 0.18 cases per 10 000 people. The number of new cases shows the degree of sustained transmission of the disease. Global statistics illustrate that 203,600 (96%) of fresh leprosy cases were from 22 key countries. Prevalence of high occurrences is a reminder that some areas around the world show high incidences of the disease and experience very high rate of transmission. According to WHO, around 16 million cases of leprosy have been treated in the last two decades. Governing bodies and governments alike are trying to eradicate the presence of the disease on a global scale. Owing to these factors, the leprosy treatment market is expected to grow at substantial rate over the forecast period (2016–2024). Request For Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/128 Leprosy Treatment Market Taxonomy On the basis of type of leprosy, the global leprosy treatment market is classified into: •Early and indeterminate leprosy treatment •Borderline tuberculoid leprosy treatment •Tuberculoid leprosy treatment •Borderline leprosy treatment •Histoid leprosy treatment •Lepromatous leprosy treatment •Borderline lepromatous leprosy treatment •Diffuse leprosy of Lucio and Latapí On the basis of treatment, the global leprosy treatment market is classified into: •Multidrug Therapy •Others As per National Leprosy Eradication Programme (NLEP), leprosy has been broadly categorized into two segments namely, paucibacillary leprosy (one to five skin lesions, maximum one nerve with skin liaisons) and multibacillary leprosy (over six skin liaisons, more than one nerve with skin liaisons). Early detection of the disease is an important factor for effective treatment, though various drugs are available for late stage leprosy patients. The most common treatment is multidrug therapy. The drugs recommended by WHO multidrug therapy are rifampicin, dapsone, and clofazimine. Among these, rifampicin is most preferred for treatment of leprosy. Treatment with everyday dapsone and monthly treatment with rifampicin for six months is followed for paucibacillary (PB or tuberculoid) cases. For multibacillary (MB or lepromatous) cases, the treatment is a prolonged one. It includes daily dapsone and clofazimine. Key Players in Leprosy Treatment Market Companies operating in the leprosy treatment market include Glaxo Smithcline Pharmaceuticals Ltd., Systopic Laboratories Pvt. Ltd., Acme Pharmaceuticals, Cadila Pharmaceuticals, Macleods Pharmaceuticals, IDPL, Astra Zeneca Pharma India Ltd., Lark Laboratories (UIndia) Ltd., Genetic Pharma, and Novartis International AG. Leprosy Treatment Market Future Outlook: Asia Pacific to be Key Growth Market Leprosy has been endemic to mankind since many decades. This needed interference of various governments around the world as well as the World Health Organization. Governments play an important role in the leprosy treatment market. Ever since the introduction of multidrug therapy by WHO in 1982, governments around the world have adopted this treatment procedure on a large scale. Some of them subsidized the treatment to eradicate the presence of the disease from their countries. Therefore government regulation as well as adoption remains the most important driver of the leprosy treatment market. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: sales@coherentmarketinsights.com
Leprosy or Hansen's disease (HD) is a chronic infection caused by Mycobacterium lepromatosis or Mycobacterium leprae bacteria. Leprosy is principally a granulomatous disease. Symptoms of leprosy include reddish skin lesions, loss of sensation, and weakness of hands and muscles. Nerve damage is the primary cause for numbness of muscles.
© Copyright 2024 Paperzz
